Filing Flows › Ideaya Biosciences (IDYA) › Q4 2024
Ideaya Biosciences (IDYA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 18, 2025
Ideaya Biosciences (IDYA) reported revenue of $7.0M for the fourth quarter 2024 (Q4 2024), +78% from a year earlier.
Ideaya Biosciences, Q4 2024: revenue $7.0M (+78% year over year), net loss $130M, operating cash flow −$122M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.0M | — | +78% |
| Operating profit | −$144M | — | — |
| Net earnings | −$130M | — | — |
| Operating cash flow | −$122M | — | — |
What changed
Revenue was $7.0M in Q4 2024, up 78% year over year.
Operating costs exceeded revenue by $144.1M, an operating margin of -2059.1%. Total costs grew 230% against revenue growth of 78%. The fastest-growing cost line was Research & development (+262%). The quarter ended with a net loss of $130.3M.
Operating cash flow was −$121.7M. Non-cash charges added back $572K of depreciation and amortization and $9.5M of share-based compensation. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$122.8M.
Questions
What was Ideaya Biosciences' revenue in the fourth quarter 2024?
Ideaya Biosciences (IDYA) reported revenue of $7.0M for the fourth quarter 2024 (Q4 2024), +78% from a year earlier.
Source: Ideaya Biosciences 10-K on SEC EDGAR.